癌症患者抑郁风险显著高于普通人群:主要癌症类型中抑郁症状的患病率与严重程度
这项在德国五个地区开展的流行病学多中心研究纳入4020例成人癌症患者和5018名基于人群的随机对照样本,采用PHQ-9评估抑郁症状。约24%的癌症患者存在抑郁(PHQ-9≥10),癌症患者抑郁的比值比是普通人群的5倍以上(OR 5.4,95%CI 4.6-6.2)。胰腺癌、甲状腺癌和脑肿瘤患者抑郁症状最重,前列腺癌和恶性黑色素瘤患者最轻。
要点
- 约每4例癌症患者中就有1例存在抑郁(PHQ-9≥10),患病率为24%。
- 癌症患者抑郁的OR为5.4(95%CI 4.6-6.2),高于普通人群5倍以上。
- 胰腺癌、甲状腺癌和脑肿瘤患者抑郁症状最重,前列腺癌和恶性黑色素瘤最轻。
核心结论
- 癌症患者抑郁的比值比是普通人群的5倍以上(OR 5.4,95%CI 4.6-6.2),约24%的癌症患者存在抑郁(PHQ-9≥10)。
- 研究结果有助于临床医生在不断增长的癌症生存人群中识别需要心理社会支持的患者。
研究设计与样本
- 流行病学多中心研究,纳入德国五个不同地区的4020例成人癌症住院和门诊患者,按全国癌症发病率进行比例分层随机抽样。
- 对照组为5018名基于人群的随机对照样本。
- 两组均填写患者健康问卷(PHQ-9)报告抑郁症状,并在校正年龄和性别的多变量分析中计算抑郁的比值比。
- 5818例符合条件患者中69%参与(女性51%,平均年龄58岁)。
主要发现
- 约每4例癌症患者中就有1例存在抑郁(PHQ-9≥10),估计患病率为24%。
- 癌症患者抑郁的比值比是普通人群的5倍以上(OR 5.4,95%CI 4.6-6.2)。
- 胰腺癌患者抑郁症状评分最高(M=8.0,SD=5.0),其次为甲状腺癌(M=7.8,SD=6.3)和脑肿瘤(M=7.6,SD=4.9)。
- 前列腺癌(M=4.3,SD=3.8)和恶性黑色素瘤(M=5.3,SD=4.3)患者抑郁症状水平最低。
临床怎么用
- 研究结果有助于临床医生在不断增长的癌症生存人群中识别需要心理社会支持的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Depression is a common co-morbidity of cancer that has a detrimental effect on quality of life, treatment adherence and potentially survival. We conducted an epidemiological multi-center study including a population-based random comparison sample and estimated the prevalence of depressive symptoms by cancer site, thereby identifying cancer patients with the highest prevalence of depression. PATIENTS AND METHODS: We included 4020 adult cancer inpatients and outpatients from five distinct regions across Germany in a proportional stratified random sample based on the nationwide cancer incidence and a comparison group consisting of 5018 participants. Both groups reported depressive symptoms by filling in the Patient Health Questionnaire (PHQ-9). In multivariate analyses adjusted for age and sex, we calculated the odds of being depressed. RESULTS: Out of 5818 eligible patients, 69% participated (51% women, mean age = 58 years). We estimated that one in four cancer patients (24%) is depressed (PHQ-9 ≥ 10). The odds of being depressed among cancer patients were more than five times higher than in the general population (OR, 5.4; 95% CI, 4.6-6.2). Patients with pancreatic (M = 8.0, SD = 5.0), thyroid (M = 7.8, SD = 6.3) and brain tumours (M = 7.6, SD = 4.9) showed the highest prevalence, whereas patients with prostate cancer (M = 4.3, SD = 3.8) and malignant melanoma (M = 5.3, SD = 4.3) had the lowest levels of depressive symptoms. CONCLUSION: Our results help clinicians identify cancer patients in need of psychosocial support when navigating in the growing survivor population.
引用
- Hartung TJ, Brähler E, Faller H, et al. The risk of being depressed is significantly higher in cancer patients than in the general population: Prevalence and severity of depressive symptoms across major cancer types. Eur J Cancer. 2016. PMID: 28024266. doi:10.1016/j.ejca.2016.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。